Thats the problem he can't buy and his negative manner won't allow him success or friendship, imagine listening to him over a shirley temple. We get to laff he gets to post ?
Sentiment: Strong Buy
Do a google search for "Equipment Innovation & Process Innovation at Mannkind" Its a PDF
The machines are modular and not huge. Looks like they are assembled from parts readily available from a list of vendors. Lots of other interesting info and pictures of the equipment.,
Sentiment: Strong Buy
WLT's outlook is only much stronger from China's ban. WLT will see $20 in 2015
To whom it may concern. You lose, I win. LOSER! Kiss my grits boy. And by the way referring to momma WHO is correct. As I said, LOSER. You haven't been here long or you would know I was mocking Colon the Harvard grad. Let's talk science, name your poison, boy!
3rd post for rocket... new id'd basher or common drowned short drowned.
Another newly hatched genius
Don't forget who controls this company. Syn may be small but will never be short on funding. I don t think trimesta is in the company's long term plans. Would be nice to get something for it but I never counted on it so anything is a bonus.
Sentiment: Strong Buy
Another Saturday night and Smitty's ain't got nobody.
Hes got no money, 'cause he's not been paid (ever).
Oh how he wishd he had someone to talk to. His Snoz's is in an awful way.
Hilarious! billy should work for the Fed! He's got all the experience and requirements, namely, possesses the ability to throw money down the sewer, and repeats the same mistakes again and again. Investing in companies that never make a profit is a rare attribute. I hereby nominate billy to Fed Chairperson. Maybe he can work underneath Yellen? All in agreement?
Well if you want to see your money stay parked or at most modest returns, it's great. C+ stock for middle class mindset.
Kerry P. Gray, ULURU's Chairman, President, and Chief Executive Officer, stated, "We believe the reverse stock split will position the Company more favourably in the financial markets and enable us to attract institutional ownership of our stock."
In your hero's words. I'm sure that he just did the R/S for the fun of it. It was a complete failure. There has been no attraction whatsoever to institutional ownership and certainly nothing favorable.
hi, you wild stallion, i don't like to think too much, but if you want everyone to "join" you when you get ready to sell, wouldn't that diminish your (and everyone's) chance of getting the highest price possible? again, a lot of this is beyond my pretty beauty queen head, but it seems you should be pumping (and not say you're going to sell) so that the pps might go up and you can get a higher price when you sell...don't mind me
It has ben reported that Sinopharm will come here to visit not only Pvct but Moffit, St. Lukes, and MD Anderson
In the Chinese culture it is customary to meet face to face before concluding any deal. It is also customary that if they mean to say no then they just fade away and say nothing. You can google chinese business deal etiquette to verify. I did that and posted link on investors village. If they are coming then my interpretation is that the deal is done. But I suggest all do dd like I did to confirm the hypothesis. I imagine that if a deal is done then the India deal will follow shortly. That leaves pacific rim which includes Japan and Australia, Europe, and the Middle East which should include North Africa and Russia. It is my opinion that a deal with China woud start the dominos and finally monetize the company which should finally draw in the big Pharma. There is no fact that this will happen but just my opinion how things should go.
Moffit, it looks like, is going to report on mouse combo study with immunotherspy, namely the pd-1 drugs they already represent with Bristol Myers Squibb and Eli Lily. They would not be presenting in November if the data was inclucusive. It would be logical that this folds into a human combo study for stage four patients....raising the cr of immunotherapies above 24%.
Now getting to the liver studies. PI for liver is ongoing and was expanded awhile back to include the combo drug nexavar. Recruitment,I have been told, has been difficult due to its toxic nature.....thus the delays. It is being finished up. Phase2/3 in the states will probably include it as well but overseas has different standard of care. China will not do Sorafinib...aka Nexavar. So there will be about four comparator drugs used in the liver trials. Now because there are no real drugs appropriate for liver cancer, the studies will go quick....probably over in one year. The protocols being finished right now are for melanoma and liver.
Just as I figured when BABA opened %30+ higher YHOO was flat. With no price movement people panicked and sold and then if was bought up again. Down $1 is about flat considering all the options pricing.
It's called timing. Lanza and advisers pumped the stock to cash out on some cash for,Alibaba.
That is speculative Of coarse. I am also surprised the stock hasn't dropped Lowerer,after all the pps had to adjust for the sell off.